On Jun. 17, 2020, CureVac announced that the German Health Authority Paul-Ehrlich-Institute and the Belgian Federal Agency for Medicines and Health Products approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection.

The trial will be conducted in Germany and Belgium. First subjects will be vaccinated at the Institute for Tropical Medicine in T�bingen and the Ghent University Hospital (Belgium), the Tropical Institute of the University Hospital Munich, LMU (Germany), and the Hannover Medical School (Germany).